SCHEMBL10200337

SCHEMBL10200337

FC(F)(F)c1cccc(-c2ccc3c(n2)OCCNC3)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.53
KDM1A O60341 3/20 0.46
CTSS P25774 1/20 0.43
CNR2 P34972 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 1/20 0.43
KMT2A Q03164 1/20 0.43
IDO1 P14902 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
AR P10275 1/20 0.41
XDH P47989 1/20 0.41
HTR2C P28335 2/20 0.40
KMO O15229 1/20 0.40
PARP10 Q53GL7 1/20 0.39
PARP11 Q9NR21 1/20 0.39
HTR1A P08908 1/20 0.39
MAOB P27338 1/20 0.39
CASP3 P42574 1/20 0.38
CASP7 P55210 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2111882 0.92 ASIC3 (0.46) ASIC3KDM1ACTSSCNR2MEN1
SCHEMBL10200361 0.84 CYP3A4 (0.36) ASIC3MEN1POLBKMT2AKDM4E
SCHEMBL10200397 0.82 PIK3CA (0.43)
SCHEMBL10200216 0.82 MAP4K4 (0.38) ASIC3CNR2IDO1HTR2CKMO
SCHEMBL10249479 0.82 IDO1 (0.38) KDM1AIDO1XDHKMOPARP10
SCHEMBL10200313 0.82 ALDH1A1 (0.38) MEN1POLBKMT2AKDM4EALDH1A1
SCHEMBL2109259 0.82 HTR2C (0.38) ASIC3MEN1KMT2AALDH1A1HTR2C
Trifluoroacetic Acid SCHEMBL2110684 0.81 ASIC3 (0.36) ASIC3KMOSCN9A
Hydrochloric Acid SCHEMBL2112997 0.80 HTR2C (0.38) ASIC3MEN1KMT2AALDH1A1HTR2C
SCHEMBL1812780 0.80 KDM1A (0.47) KDM1ACTSSCNR2MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150238506-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-08-27 US disclosed
US-9079907-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-07-14 US disclosed
US-20120165312-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SHIRAI JUNYA (JP) 2012-06-28 US disclosed
US-8158617-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-17 US disclosed
US-8158617-B2 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-17 US disclosed
US-20090131402-A1 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-05-21 US disclosed
US-20090131402-A1 Fused heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165312-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF HTR2C, HTR3C, HTR3B ASIC3 969/4885KDM1A 2568/4885CTSS 2254/4885
US-20090131402-A1 Fused heterocyclic compound and use thereof HTR2C, HTR3C, HTR3B ASIC3 969/4885KDM1A 2568/4885CTSS 2254/4885
US-20150238506-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF HTR2C, HTR3C, HTR3B ASIC3 969/4885KDM1A 2568/4885CTSS 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.